ResMed RMD
Healthcare · Medical - Instruments & Supplies · Synthos Deep Dive · 2026-07-03
The Overview
ResMed makes the machines and masks that treat sleep apnea — the CPAP device on the nightstand that keeps people breathing at night — plus software for home-health providers. It is the clear #1 in its field, very profitable (it keeps about 27 cents of every sales dollar as profit), and carries more cash than debt.
Here's the twist. When new weight-loss drugs like Ozempic and Zepbound took off, investors worried that thinner people would need fewer sleep-apnea machines, and they knocked the stock down about 29% from its peak. But so far ResMed's sales are still growing ~10% a year — the feared collapse hasn't shown up in the numbers. So the stock is now cheaper than it usually is, roughly a normal market price for a better-than-average company.
Our verdict is Buy — Tactical: worth owning as a bargain-priced quality name, but not a "sleep-easy forever" holding, because that drug worry is real and unresolved.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe). Strong balance sheet, steady stock, reasonable price — the danger is the drug story, not the finances.
- Growth Quality 6/10 (good, not spectacular). Grows steadily around 8–11% a year and is very profitable, but it is a mature, one-category business.
- Exponential Potential 3/10 (low). Don't expect it to double fast — it is a solid grinder in a slow-growing market, not a rocket.
The one big worry: if weight-loss drugs really do shrink the number of people who need CPAP machines over the next decade, ResMed's growth could stall. The whole debate rides on whether that happens — and so far it hasn't.
Putting a number on it: our fair-value estimate is $255 against a current price of $240.33 — real upside if our numbers are right.
Our summary metrics
Net cash, beta 0.78, 20× earnings — cheap for the quality; risk is the GLP-1 secular overhang, not the balance sheet.
~8% fwd revenue / ~11% fwd EPS CAGR, 62% gross margin rising, 24% ROE, durable device-plus-mask razor/blade moat.
High-quality compounder but decelerating, mature category, $30B cap in a slow-growth TAM — not a multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
High-quality compounder but decelerating, mature category, $30B cap in a slow-growth TAM — not a multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $261 (high $314 / low $225; 15 Buy · 15 Hold · 5 Sell) — context, not our anchor |
| Valuation | 20× trailing EPS · 19× FY26E · 17× FY27E · 13× FY30E · EV/S 5.3× · EV/EBITDA 13.5× |
| Technicals | Downtrend — $209.63, −28.6% off 52-wk high, below the 200-DMA, RSI 68, −18% 12-mo (SPY +21%) |
| Conviction | Low breadth — 0 net-bullish voices, 0 KB claims; call rests on fundamentals + quant |
| Position sizing | Tactical value add, ~2–4% — a de-rated quality name, sized as a satellite not a core anchor |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for RMD — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $240.33, 14% above the 50-day average ($211), 5% above the 200-day average ($229) — an uptrend. 15% below the 52-week high of $283, 31% above the 52-week low of $183.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $240.33 is currently inside the band (band $212–$241).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 69.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.83, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = RMD · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
ResMed Inc. (NYSE: RMD) is a San Diego–based global medical-technology company founded in 1989, the global leader in devices and software for sleep apnea and respiratory care. Its razor-and-blades model pairs flow-generator devices (CPAP/APAP/bi-level machines) with high-margin, recurring mask and accessory resupply, wrapped in cloud software (AirView, myAir) and a home-medical-equipment software suite (Brightree, MatrixCare, HEALTHCAREfirst). It serves ~140 countries. Fiscal year ends June 30.
Revenue mix (FY2024 segmentation, latest in FMP):
- By segment: Sleep & Respiratory Care $4.10B (88%) · Software-as-a-Service (Residential Care Software) $0.58B (12%). The core device+mask franchise is the engine; SaaS is a steadier, stickier tail.
- By geography (FY2024): U.S. $2.98B (~64%) · rest-of-world / Global $1.71B (~36%). (FMP's older-year geo tags are noisy; the current split is roughly two-thirds U.S., one-third international.)
FY25 total revenue was $5.15B, and the nine months of FY26 through March 2026 ran $4.19B (+10% YoY) — the mix is unchanged and the device+mask core is still carrying growth (per the Q3 FY26 release, §9).
2. The expert thesis (traceability)
There is no expert coverage of RMD in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. There are no claim_id values to cite, and this note fabricates none.
That absence is itself information: RMD is not a name the high-skill voices Synthos tracks (macro/tech/AI-forward investors) spend time on — it is an unglamorous, mature medical-device compounder, not a next-exponential. The verdict here is therefore entirely fundamentals- and quant-driven: it rests on the reported financials, the analyst-consensus estimate path, valuation, and the structural read of the GLP-1 debate — not on any conviction panel. Readers should weight this note accordingly: it carries no breadth signal, only the numbers and our reading of them.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Net cash (net-debt/EBITDA −0.37×), beta 0.78, current ratio 3.0, 20× earnings — financially sturdy and not expensive. The risk is not the balance sheet; it is the GLP-1 secular overhang and a chart that is still below its 200-DMA. |
| Growth Quality | 6 · Good | ~8% forward revenue CAGR, ~11% forward EPS CAGR, gross margin rising (59%→62% YoY), 24% ROE / 20% ROIC, a durable device+recurring-mask moat. Solid, but single-category and mid-single/low-double-digit, not elite. |
| Exponential Potential | 3 · Low | Decelerating growth in a mature category; $30B cap in a TAM that is not rapidly expanding. A high-quality grinder, structurally not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | GLP-1 fear proves overblown (drugs expand diagnosis and adherence rather than shrink the funnel); growth reaccelerates. FY27E EPS beats to ~$13.0 (vs $12.24 cons); multiple re-rates back to a quality ~26×. | ~$338 (+61%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$12.24; the GLP-1 overhang caps the multiple at a market-level ~21× despite above-market quality. | ~$255 (+22%) |
| Bear | GLP-1 adoption visibly slows new-patient starts; growth fades toward mid-single digits and the market de-rates a "melting-ice-cube-someday" narrative. FY27E EPS ~$11.3; multiple compresses to ~17×. | ~$190 (−9%) |
Synthos fair value = the base case, ~$255 (+22%), with the full $190–$338 span as the honest range. This anchor sits essentially on top of the Street's $261 consensus — unusual for us, and a sign the value case is not a contrarian stretch but a straightforward "quality at a market multiple" call. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). RMD is squarely a compounder, and a decelerating one — hence the low Exponential score:
- Forward growth: revenue CAGR FY25→FY30E ~8.4% ($5.15B → $7.70B, est.); EPS CAGR ~11.2% ($9.51 → $16.15, est.) as margins and buybacks help.
- Acceleration (the 2nd derivative) is roughly flat-to-negative: revenue growth +9.8% (FY25) → +9.8% (FY26E) → +7.6% (FY27E) → +6.9% (FY28E) on consensus. No inflection up; the category grows steadily, not exponentially. Per our flagship philosophy we pick forward next-exponentials over trailing compounders — RMD is a trailing-style compounder, the opposite profile.
- Room to run: the sleep-apnea TAM is large (hundreds of millions undiagnosed globally) but penetration grows slowly and is now clouded by the GLP-1 question. At $30B cap the name can compound, but a 3–5× would require either a category re-acceleration or a multiple the market is unwilling to pay under the drug overhang.
- Reinvestment runway: modest capex (~2.6% of revenue), high FCF conversion, cash returned via buybacks + a growing dividend — a return-of-capital compounder, not a reinvestment exponential.
Exponential Potential: Low (3/10). Own RMD for durable ~10% earnings compounding at a de-rated price, not for a fast multibagger. A $30B mature device leader with single-digit revenue growth simply cannot score where an accelerating small-cap would.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $5.15B, +9.8% (FY24 $4.69B, +11% on FY23 $4.22B). Steady low-double-digit growth. Nine months FY26 $4.19B, +10% YoY.
- Quarterly trajectory: Q3 FY25 $1.29B → Q4 $1.35B → Q1 FY26 $1.34B → Q2 $1.42B → Q3 FY26 $1.43B (+11% YoY). No sign of GLP-1-driven decline in the actuals.
- Margins: gross 61.7% TTM and rising (Q3 FY26 GAAP GM 62.2%, +290 bps YoY on component-cost and logistics gains), EBIT margin 34.9% TTM, net margin 27.4% TTM. Genuine operating leverage.
- Earnings: net income $1.40B FY25 (+37% on FY24's $1.02B), diluted EPS $9.51. TTM EPS ~$10.37. The FY25 jump was flattered by lower one-offs vs FY24; the underlying run-rate is high-single/low-double-digit EPS growth.
- Cash flow: operating CF $1.75B FY25, capex only ~−$90M, FCF ~$1.66B (FCF margin ~32%). Elite cash conversion (FCF/OCF ~92%).
- Balance sheet: total debt $0.85B against $1.21B cash → net cash ~$0.36B, net-debt/EBITDA −0.37×. Interest coverage 65×. Fortress. The 2023 Brightree/MatrixCare-era leverage has been fully paid down (net debt was $1.35B in FY23).
6. Valuation — priced in or room?
For a franchise with 62% gross margins, 24% ROE and net cash, 20× trailing earnings is not expensive — it is roughly a market multiple for a clearly above-market-quality business. On live consensus the forward P/E is 19× (FY26E) → 17× (FY27E) → 13× (FY30E); EV/EBITDA is 13.5× and EV/sales 5.3×. The multiple has compressed because of the GLP-1 narrative, not because of any deterioration in the numbers — margins are expanding and growth is intact. A simple read: if the market ever re-rates RMD back to the ~25–30× it historically commanded as a steady compounder, the stock re-rates ~30–50% on flat estimates alone. Street targets (context): consensus $261, high $314, low $225 — our $255 base FV sits right at consensus, which for us is a tell that the value case is consensus-safe, not a heroic contrarian bet. Not a deep-value screen-buy; a quality-compounder-at-a-market-multiple buy, with the drug overhang the reason it's not cheaper.
7. Technicals (from the tech block)
- Trend: down. $209.63 sits above the 50-DMA ($201.71) but well below the 200-DMA ($239.14) — a death-cross posture; the primary trend is down even as a short-term bounce is underway.
- Location: −28.6% off the 52-week high ($293.73), +14.7% off the 52-week low ($182.82); max drawdown from peak −29.5%. This is a de-rated, out-of-favor chart, not a leadership name.
- Momentum: RSI(14) 68 — near-term hot after a bounce (the quote shows +4.2% on the day), approaching but not through overbought (<70). MACD barely positive (+0.11).
- Relative strength (the tell): RMD −18.2% 12-mo vs SPY +20.6% and QQQ +30.3%; −5.9% 3-mo vs SPY +13.7%. Persistent, heavy underperformance — the market has been selling this name, consistent with the GLP-1 fear, not the fundamentals.
- Read: technicals do not confirm the fundamental value case — the trend is down and RSI is stretched after a one-day pop. This argues for scaling in on weakness / below the 200-DMA rather than chasing the bounce. A reclaim of the 200-DMA (~$239) would be the technical confirmation the de-rating is ending.
8. Moat & competitive position
ResMed's moat is a durable razor-and-blades franchise: it holds roughly half the global sleep-device market in a stable duopoly with Philips (whose Respironics recall handed ResMed years of share gains), and the recurring mask + accessory resupply stream — reordered on a schedule, cloud-tracked via AirView/myAir — is high-margin and sticky. Switching costs run through home-medical-equipment providers and payers, and the Brightree/MatrixCare software layer deepens that lock-in. The competitive threats are (1) the GLP-1 secular question (does obesity treatment shrink the funnel), (2) Philips's recovery post-recall, and (3) payer/reimbursement pressure on device pricing.
Peer set (FMP-supplied, market cap): Agilent $37B, Alcon $34B, Becton Dickinson $57B, Cardinal Health $56B, GE HealthCare $30B, Haleon $43B, Humana $48B, Insmed $24B, IQVIA $35B, Mettler-Toledo $26B. Note: this is a broad "healthcare / med-tech" bucket, not pure sleep-apnea comps — RMD has no clean public pure-play peer; its truest comparator (Philips's sleep unit) is embedded in a conglomerate. Within this group RMD carries top-tier margins and ROE at a mid-pack multiple.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly — modest capex (~$90M/yr), consistent buybacks (673K shares / $175M repurchased in Q3 FY26 alone), and a growing dividend ($0.60/qtr, ~1.1% yield), all funded comfortably by ~$1.66B FCF while holding net cash. Bolt-on M&A (VirtuOx, and a flagged strategic/portfolio review) is measured. CEO Mick Farrell has run the company since 2013.
- Insider activity: the recent Form 4s from CEO Farrell are option-exercise-and-sell transactions (M-Exempt exercise at $146.34 then S-Sale at $193–208), i.e. routine 10b5-1-style monetization of vested options, not discretionary open-market selling of a red-flag nature. Two new officer Form 3/4 filings (Bloomer, Sandercock) are onboarding, not trades.
- Management's own guidance (half-weighted, self-interested): the SEC 8-K/earnings release for Q3 FY26 (filed 2026-04-30) is a genuine results release, and CEO Farrell's forward language is: "we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth," citing continued double-digit revenue growth, 290 bps of gross-margin expansion and 21% non-GAAP EPS growth in the quarter. However, the release contains no explicit numeric forward guidance (no revenue or EPS range for FY26/FY27) — ResMed's practice is qualitative. So: management's tone is confidently bullish on continued profitable growth, but there is no company-issued numeric outlook to weight; the forward numbers in this note are analyst consensus, labeled as estimates.
10. Catalysts & what to watch
- Next earnings: 2026-08-06 (Q4 FY26 + full-year FY26; Street EPS $2.90, revenue ~$1.47B). The key line: U.S. device + new-patient-setup growth — the direct read on whether GLP-1 is denting the funnel.
- GLP-1 / obesity data: any real-world evidence on whether weight-loss-drug users stay on or drop CPAP — the single biggest swing factor. (Emerging data has actually suggested treated OSA + GLP-1 can be complementary, supporting the bull case.)
- Gross-margin trajectory: continuation of the +290 bps expansion = confirmation of pricing/cost discipline.
- Philips competitive recovery: share dynamics as Respironics returns.
- Multiple re-rating: a reclaim of the 200-DMA (~$239) would signal the de-rating narrative is breaking.
Thesis tripwires (what would change the call): two consecutive quarters of U.S. device revenue deceleration below mid-single digits; gross-margin rollover; or hard evidence of GLP-1-driven attrition in the resupply base.
11. Key risks
- GLP-1 / obesity-drug secular threat (the whole bear case): if weight-loss drugs materially shrink the sleep-apnea population or reduce CPAP adherence, RMD's growth and multiple both compress. This is the single reason the stock is de-rated and the dominant risk. (So far unconfirmed in the actuals — but unresolved.)
- Multiple stays de-rated: even if fundamentals hold, the market may keep RMD at ~17–20× under the overhang, capping returns to earnings growth.
- Single-category concentration: ~88% of revenue is sleep & respiratory — little diversification if that one category stumbles.
- Reimbursement / pricing pressure: device pricing is exposed to payer and DME-channel dynamics.
- Competitive: Philips's post-recall recovery could slow ResMed's share gains.
- No expert breadth: unlike a conviction name, there is no external panel corroborating (or contesting) this call — it is quant/fundamental only.
12. Verdict, position sizing & monitoring
Buy — Tactical. RMD is a high-quality, net-cash, cash-generative device leader (FY25 revenue $5.15B, 24% ROE, ~$1.66B FCF, gross margins expanding) that has been sold down ~29% from its high on a GLP-1 fear that has not yet appeared in the numbers — leaving an above-market-quality compounder at a roughly market multiple (20× trailing, 17× FY27E). That is a genuinely attractive setup. It is Tactical rather than Core because (a) there is zero expert breadth behind it, (b) the secular overhang is real and unresolved, and (c) the chart is still in a downtrend below its 200-DMA.
- Sizing: tactical, ~2–4% of the flagship — a de-rated quality name to own opportunistically, sized as a satellite, not a core anchor. Scale in on weakness rather than chasing the bounce; the down-trend argues for patience.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with special attention to U.S. device growth and any GLP-1 attrition signal. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $209.63.
- Single biggest risk: GLP-1 / obesity drugs shrinking the sleep-apnea funnel — the entire de-rating, and the entire bear case, live here.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of RMD in the Synthos knowledge base, so no
claim_ids are cited and none are fabricated. This is explicitly a fundamentals- and quant-driven note. - Data as-of: fundamentals 2026-03-31 (Q3 FY26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: the Q3 FY26 earnings release is genuine but contains no numeric forward guidance; management's qualitative "strong, profitable growth" tone is its own self-interested book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").